6533b7d6fe1ef96bd1265b9a
RESEARCH PRODUCT
A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis.
Nir YogevThomas BukurÖZlem TüreciJutta PetschenkaJutta PetschenkaMustafa DikenÖZlem Akilli-öztürkMichael StreuberHendrik BergerAri WaismanElif DikenLaura KolbLena M. KranzUgur SahinSebastian KreiterKatalin KarikóChristina KrienkeSarah Kirchhoffsubject
Encephalomyelitis Autoimmune ExperimentalMultiple SclerosisRegulatory T cellEncephalomyelitisAntigen presentationAntigen-Presenting CellsAutoantigensT-Lymphocytes RegulatoryMiceImmune systemAntigenmedicineAnimalsRNA MessengerAntigen-presenting cellImmunosuppression TherapyInflammationVaccines SyntheticMultidisciplinarybusiness.industryEffectorExperimental autoimmune encephalomyelitisBystander Effectmedicine.diseaseMice Inbred C57BLmedicine.anatomical_structureImmunologybusinessPseudouridinedescription
Precision therapy for immune tolerance Autoimmune diseases, such as multiple sclerosis (MS), result from a breach of immunological self-tolerance and tissue damage by autoreactive T lymphocytes. Current treatments can cause systemic immune suppression and side effects such as increased risk of infections. Krienke et al. designed a messenger RNA vaccine strategy that lacks adjuvant activity and delivers MS autoantigens into lymphoid dendritic cells. This approach expands a distinct type of antigen-specific effector regulatory T cell that suppresses autoreactivity against targeted autoantigens and promotes bystander suppression of autoreactive T cells against other myelin-specific autoantigens. In mouse models of MS, the vaccine delayed the onset and reduced the severity of established disease without showing overt symptoms of general immune suppression. Science , this issue p. 145
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2019-06-13 | Science (New York, N.Y.) |